Molrine, DeborahAntin, Joseph H.Guinan, Eva C.Soiffer, Robert J.MacDonald, KristinMalley, RichardMalinoski, Frank J.Trocciola, SusanWilson, MarjorieAmbrosino, Donna M.2022-08-232022-08-232002-10-242008-04-14Blood. 2003 Feb 1;101(3):831-6. Epub 2002 Sep 19. <a href="http://dx.doi.org/10.1182/blood-2002-03-0832">Link to article on publisher's site</a>0006-4971 (Print)10.1182/blood-2002-03-083212393732https://hdl.handle.net/20.500.14038/39991Patients undergoing hematopoietic cell transplantation (HCT) are at increased risk for infections with Streptococcus pneumoniae and have long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines. We examined whether donor immunization with a heptavalent pneumococcal conjugate vaccine (PCV7) would elicit protective antibody responses to additional doses of vaccine administered early after transplantation. Ninety-six patients scheduled to receive an allogeneic hematopoietic cell transplant were randomized with their donors to receive either a dose of PCV7 vaccine or no vaccine before transplantation. All patients received PCV7 at 3 months, 6 months, and 12 months following transplantation, and serotype-specific antibody concentrations were determined after each dose. Following HCT, geometric mean antibody concentrations of patients in the immunized donor group were significantly higher for 5 of the 7 vaccine serotypes after one dose (P <.05) and for 4 of the 7 serotypes after 2 doses of vaccine (P <.03). Sixty-seven percent of patients in the immunized donor group had presumed protective IgG concentrations more than or equal to 0.50 microg/mL to all 7 serotypes following the first dose of vaccine compared to 36% in the unimmunized donor group (P =.05). After the third dose of vaccine, both groups had more than 60% of patients with concentrations at least 0.50 microg/mL to all vaccine serotypes. Donor immunization enhances early antibody responses of patients undergoing HCT to pneumococcal conjugate vaccine. A 3-dose schedule of PCV7 vaccine at 3, 6, and 12 months is immunogenic in these patients regardless of donor immunization.en-USAdolescentAdultAgedAntibodies, BacterialAntibody FormationChildChild, PreschoolFemaleHematopoietic Stem Cell TransplantationHumans*ImmunizationMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesTime Factors*Tissue DonorsTransplantation, HomologousVaccines, ConjugateMedical Cell BiologyMedical ImmunologyJournal Articlehttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1279&amp;context=oapubs&amp;unstamped=1https://escholarship.umassmed.edu/oapubs/280489617oapubs/280